Predictive variables of the progression to androgen independent prostate cancer after combined androgen blockade

Korean Journal of Urology

Volumn 48, Issue 4, 2007, Pages 408-415

  Park, Seung Chol ^h   Choi, Han Yong ^a   Kim, Choung Soo ^b   Hong, Sung Joon ^c   Kim, Wun Jae ^d   Lee, Sang Eun ^e   Song, Jae Mann ^f   Yoon, Jin Han ^g   Rim, Joung Sik ^h  

^a Sungkyunkwan University   (South Korea)

^b University of Ulsan   (South Korea)

^c Yonsei University   (South Korea)

^d Chungbuk National University   (South Korea)

^e Seoul National University   (South Korea)

^f Yonsei University Wonju   (South Korea)

^g Dong A University College of Medicine   (South Korea)

^h Wonkwang University   (South Korea)

Author keywords

Hormone; Progression; Prostate cancer

Indexed keywords

ANTIANDROGEN; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER STAGING; DISEASE COURSE; FOLLOW UP; GLEASON SCORE; HORMONE DEPENDENCE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; LOGISTIC REGRESSION ANALYSIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORCHIECTOMY; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; ROC CURVE; UNIVARIATE ANALYSIS;

EID: 34247849288     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: 10.4111/kju.2007.48.4.408     Document Type: Article

References (20)

1. Ministry of Health and Welfare Republic of Korea. 2002 Annual Report of the Korea Central Cancer Registry. 2002; 11-4
2. Korea National Statistical Office. Annual report on the cause of death statistics (based on vital registration)
3. Derweesh IH, Kupelian PA, Zippe C, Levin HS, Brainard J, Magi-Galluzzi C, et al. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol 2004;22:300-6
4. Denis LJ, Keuppens F, Smith PH, Whelan P, deMoura JL, Newling D, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998;33:144-51
5. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006;106:1708-14
6. Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. J Urol 1997;158:160-3
7. Denis LJ, Carnelro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993; 42:119-29
8. Kim KH, Seo YJ, Lee KS. The factors affecting prognosis in patients with metastatic prostate cancer after hormonal therapy. Korean J Urol 2004;45:24-8
9. Benaim EA, Pace CM, Lam PM, Roehrborn CG. Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology 2002;59:73-8
10. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormonal therapy for prostate cancer. J Urol 2002;168:995-1000
11. Park BJ, Lee YG, Ahn HK. Prognostic significance of prostate-specific antigen level two months after maximal androgen blockade in metastatic prostate cancer. Korean J Urol 2003;44: 855-60
12. Morote J, Trilla E, Esquena S, Abascal JM, Reventos J. Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Cancer 2004;108:877-81
13. Cooper EH, Armitage TG, Robinson MR, Newling DW, Richards BR, Smith PH, et al. Prostate specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer 1990;66(5 Suppl): 1025-8
14. Miller JI, Ahmann FR, Drach GW, Emerson SS, Botaccini MR. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992;147:956-61
15. Daver A, Soret JY, Coblentz Y, Allain YM, Cellier P, Chauveau P. The usefulness of prostate-specific antigen and prostatic acid phosphatase in clinical practice. Am J Clin Oncol 1988;11(Suppl 2):S53-60
16. Lee SY, Kim YS, Hong SJ. Clinical response of combined androgen blockade in metastatic prostate cancers. Korean J Urol 2000;41:361-6
17. Oosterlinck W, Mattelaer J, Casselman J, Van Velthoven R, Derde MP, Kaufman L. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients. Acta Urol Belg 1997;65:63-71
18. Benaim EA, Pace CM, Roehrborn CG. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urol 2002;42:12-7
19. Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, et al. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int 2005;96:503-7
20. Morote J, Esquena S, Abascal JL, Trilla E, Cecchini L, Raventos CX, et al. Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer. Int J Biol Markers 2005;20:209-16